Published in Antivir Chem Chemother on January 01, 2009
A perspective of the dynamic structure of the nucleus explored at the single-molecule level. Chromosome Res (2011) 0.81
Fluctuations in Tat copy number when it counts the most: a possible mechanism to battle the HIV latency. Theor Biol Med Model (2013) 0.75
Identification of benzazole compounds that induce HIV-1 transcription. PLoS One (2017) 0.75
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A (2008) 2.22
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol (2007) 2.16
Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes Dev (2006) 2.02
Identification of a human endonuclease complex reveals a link between tRNA splicing and pre-mRNA 3' end formation. Cell (2004) 1.80
A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol (2005) 1.80
Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J Virol (2002) 1.72
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63
Nuclear mRNA surveillance. Curr Opin Cell Biol (2003) 1.56
Global analysis of Pub1p targets reveals a coordinate control of gene expression through modulation of binding and stability. Mol Cell Biol (2005) 1.50
Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve (2014) 1.41
Non-stop decay--a new mRNA surveillance pathway. Bioessays (2002) 1.28
The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. J Virol (2004) 1.27
Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A (2009) 1.09
Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem (2002) 1.09
High rate of genetic recombination in murine leukemia virus: implications for influencing proviral ploidy. J Virol (2006) 1.08
Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol (1985) (2010) 1.02
Cleavage of pre-tRNAs by the splicing endonuclease requires a composite active site. Nature (2006) 1.02
A yeast homologue of Hsp70, Ssa1p, regulates turnover of the MFA2 transcript through its AU-rich 3' untranslated region. Mol Cell Biol (2003) 1.01
Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. Hepatology (2003) 1.00
Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther (2012) 1.00
Role for Upf2p phosphorylation in Saccharomyces cerevisiae nonsense-mediated mRNA decay. Mol Cell Biol (2006) 0.98
High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem (2011) 0.97
Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob Agents Chemother (2005) 0.94
p38 mitogen-activated protein kinase/Hog1p regulates translation of the AU-rich-element-bearing MFA2 transcript. Mol Cell Biol (2005) 0.90
Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen. Blood (2004) 0.88
Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Antimicrob Agents Chemother (2013) 0.85
Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemother (2003) 0.83
A HIV-2-based self-inactivating vector for enhanced gene transduction. J Biotechnol (2006) 0.83
Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. J Med Chem (2013) 0.82
Mining the GEMS--a novel platform technology targeting post-transcriptional control mechanisms. Drug Discov Today (2007) 0.81
Post-transcriptionally regulated expression system in human xenogeneic transplantation models. Mol Ther (2011) 0.78
Host stem cells can selectively reconstitute missing lymphoid lineages in irradiation bone marrow chimeras. Blood (2003) 0.77
Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorg Med Chem Lett (2013) 0.77
Proviral progeny of heterodimeric virions reveal a high crossover rate for human immunodeficiency virus type 2. J Virol (2006) 0.77
Choice and use of appropriate packaging cell types. Methods Mol Biol (2003) 0.77
Gunvalson and PTC Therapeutics' community outreach. Nat Biotechnol (2009) 0.75
Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication. Bioorg Med Chem Lett (2013) 0.75
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. J Cyst Fibros (2011) 0.75
Cross-reactive antibodies induced by xenogeneic IgA can cause selective IgA deficiency. Autoimmunity (2010) 0.75